Loading...
Alnylam Pharmaceuticals, Inc.
ALNY•NASDAQ
Healthcare
Biotechnology
$401.80
$9.56(2.44%)
Alnylam Pharmaceuticals, Inc. (ALNY) Financial Performance & Income Statement Overview
Review Alnylam Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
22.97%
↑ 22.97%
Operating Income Growth
37.31%
↑ 37.31%
Net Income Growth
36.82%
↑ 36.82%
Operating Cash Flow Growth
-107.98%
↓ 107.98%
Operating Margin
-7.32%
↓ 7.32%
Gross Margin
58.02%
↑ 58.02%
Net Profit Margin
-12.96%
↓ 12.96%
ROE
-274.21%
↓ 274.21%
ROIC
-5.52%
↓ 5.52%
Alnylam Pharmaceuticals, Inc. (ALNY) Income Statement & Financial Overview
Review Alnylam Pharmaceuticals, Inc.'s (ALNY) income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $773.69M | $594.19M | $593.17M | $500.92M |
| Cost of Revenue | $0.00 | $71.04M | $102.82M | $85.91M |
| Gross Profit | $0.00 | $523.15M | $490.35M | $415.01M |
| Gross Profit Ratio | $0.00 | $0.88 | $0.83 | $0.83 |
| R&D Expenses | $323.62M | $265.12M | $300.17M | $270.93M |
| SG&A Expenses | $323.31M | $239.95M | $295.34M | $220.99M |
| Operating Expenses | $646.93M | $505.07M | $595.51M | $491.92M |
| Total Costs & Expenses | $789.89M | $576.11M | $698.33M | $577.82M |
| Interest Income | $27.49M | $28.67M | $31.02M | $32.15M |
| Interest Expense | -$40.25M | $38.65M | $38.97M | $34.38M |
| Depreciation & Amortization | $0.00 | $14.40M | $14.17M | $13.98M |
| EBITDA | -$16.20M | $11.46M | -$140.91M | -$60.30M |
| EBITDA Ratio | -$0.02 | $0.02 | -$0.24 | -$0.12 |
| Operating Income | -$16.20M | $18.08M | -$105.16M | -$76.91M |
| Operating Income Ratio | -$0.02 | $0.03 | -$0.18 | -$0.15 |
| Other Income/Expenses (Net) | -$19.16M | -$59.67M | -$88.80M | -$31.76M |
| Income Before Tax | -$35.36M | -$41.60M | -$193.96M | -$108.66M |
| Income Before Tax Ratio | -$0.05 | -$0.07 | -$0.33 | -$0.22 |
| Income Tax Expense | -$30.92M | $15.88M | -$110.19M | $2.91M |
| Net Income | -$66.28M | -$57.48M | -$83.76M | -$111.57M |
| Net Income Ratio | -$0.09 | -$0.10 | -$0.14 | -$0.22 |
| EPS | -$0.51 | -$0.44 | -$0.65 | -$0.87 |
| Diluted EPS | -$0.51 | -$0.44 | -$0.65 | -$0.87 |
| Weighted Avg Shares Outstanding | $130.63M | $129.68M | $128.59M | $128.59M |
| Weighted Avg Shares Outstanding (Diluted) | $130.63M | $129.68M | $128.59M | $128.59M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan